Biomea Fusion, Inc. - 8-K Filing

Biomea Fusion announces topline results from its ongoing Phase 1 GLP-131 clinical trial for investigational oral small molecule GLP-1 receptor agonist BMF-650. (Items: 7.01 Regulation FD Disclosure On October 13, 2026, Biomea Fusion, Inc, 8.01 Other Events On October 13, 2026, the Company issued a press release titled, “Biomea Fusion Announces Phase 1 Results for BMF-650, its Invest, 9.01 Financial Statements and Exhibits)

SEC EDGAR · October 14, 2026, 10:01 UTC

Tickers: $BMEA

Read the full article at SEC EDGAR

Part of the story Zenas BioPharma, Inc. - 8-K Filing (3 articles)

More Regulatory news

UNITED BANCORP INC /OH/ - 10-Q Filing SEC EDGAR · November 12, 2026, 15:33 UTC
PATRIOT GOLD CORP - 10-Q Filing SEC EDGAR · November 12, 2026, 15:32 UTC
First Digital Acquisition Corp Ltd. - 8-K Filing SEC EDGAR · November 12, 2026, 15:29 UTC
GROOVE BOTANICALS INC. - 10-Q Filing SEC EDGAR · November 12, 2026, 15:24 UTC
Johnson Controls International plc - 10-K Filing SEC EDGAR · November 12, 2026, 15:24 UTC
OLD NATIONAL BANCORP /IN/ - 8-K Filing SEC EDGAR · November 12, 2026, 15:20 UTC
AMTECH SYSTEMS INC - 8-K Filing SEC EDGAR · November 12, 2026, 15:16 UTC
REGIONAL HEALTH PROPERTIES, INC - 8-K Filing SEC EDGAR · November 12, 2026, 15:09 UTC
Bitwise Avalanche ETF - 8-K Filing SEC EDGAR · November 12, 2026, 15:06 UTC
MiNK Therapeutics, Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 15:05 UTC